vTv Therapeutics (VTVT) Insider Al-Marzooqi Buys $210K of Stock
Fahed Al-Marzooqi purchased 6,000 shares of VTVT, highlighting insider confidence.
Reviewed by automated data checks against the source filing. How we make and check alerts
Fahed Al-Marzooqi bought 6,000 shares of vTv Therapeutics Inc. ($VTVT) at an average price of $35.08, worth about $210,480, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $VTVT is down 1.5% after 1 week, down 11.6% after 1 month and down 24.3% to date (from the $35.08 close on Jun 26, 2026).
VTVT
vTv Therapeutics Inc.
Key Points
- Fahed Al-Marzooqi bought 6,000 shares of VTVT at $35.08 per share on June 26, 2026, for a total of $210,480.
- Shares of VTVT traded near $36.27 on Tuesday, with analysts maintaining a positive outlook.
- SAMSARA BIOCAPITAL and FMR LLC adjusted their holdings in VTVT, reflecting varied institutional interest.
Get $VTVT trade alerts by text
We text you when insiders, Congress or big funds trade $VTVT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated vTv Therapeutics Inc. alert may contain errors. Disclosures
Fahed Al-Marzooqi has made a significant move by purchasing 6,000 shares of VTVT at a price of $35.08 each on June 26, 2026. This acquisition amounts to a total value of $210,480. Such insider buying often signals a belief in the company's potential.
Insider Buying and Selling at vTv Therapeutics Inc.
On June 26, 2026, several insiders, including Fahed Al-Marzooqi, bought shares of VTVT. Al-Marzooqi acquired 6,000 shares at an average price of $35.08. Other insiders, such as AKKARAJU SRINIVAS, PHILLIPS ANNE, and SEKHRI PAUL, also made similar purchases, indicating a collective insider confidence in the company's future.
Other Institutional Activity in VTVT
Institutional investors have shown varied interest in VTVT. SAMSARA BIOCAPITAL, LLC held steady with 298,496 shares valued at approximately $11.8 million. FMR LLC reduced its stake by 8,465 shares, ending with 260,391 shares worth about $10.3 million, marking a 3.1% decrease. Meanwhile, MILLENNIUM MANAGEMENT LLC opened a new position with 206,288 shares valued at around $8.2 million. TRAILS EDGE CAPITAL PARTNERS, LP significantly reduced its holdings by 91,422 shares to 139,578 shares, a 39.6% decrease.
vTv Therapeutics Inc. Stock Up 14.1%
Shares of VTVT traded near $36.27 on Tuesday. While specific financial metrics for VTVT are not detailed, the stock's recent insider and institutional activity suggests a dynamic investment landscape.
Analysts Set New Price Targets
Analyst coverage of VTVT remains positive. On March 12, 2026, Evercore ISI Group initiated coverage with a 'buy' rating and a price target of $44. BTIG maintained its 'buy' rating with a target of $49 on January 27, 2026. Roth Capital also initiated coverage with a 'buy' rating and a target of $58. The consensus among analysts is bullish, reflecting strong expectations for VTVT's market performance.
Bottom Line
Fahed Al-Marzooqi's purchase of VTVT shares underscores insider confidence in the company's prospects. While insider transactions can be a good indicator of future performance, they are just one piece of the puzzle. Investors should also consider the broader context, including institutional moves and analyst ratings, to better understand VTVT's potential in the market.
Related Filing Alerts
Source: Fahed Al-Marzooqi's Form 4 filing on $VTVT (Jun 26, 2026). Find the original filing: VTVT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts